Evidence map›Paper›PMID 39041606›Full record

ArticleJNCI cancer spectrum2024

Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics.

Ivy Altomare, Xiaoliang Wang, Maneet Kaur, Jenny S Guadamuz, Sam Falk, Forrest Xiao, Neal J Meropol, Yihua Zhao

Abstract readComparative Study
In one paragraph

Article in JNCI cancer spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ivy AltomareFlatiron Health, Inc, New York, NY, USA.ORCID 0000-0002-1222-885X
Xiaoliang WangFlatiron Health, Inc, New York, NY, USA.ORCID 0000-0001-5184-2935
Maneet KaurFlatiron Health, Inc, New York, NY, USA.ORCID 0000-0002-5231-1260
Jenny S GuadamuzFlatiron Health, Inc, New York, NY, USA.ORCID 0000-0002-2312-4140
Sam FalkFlatiron Health, Inc, New York, NY, USA.ORCID 0009-0006-8744-7551
Forrest XiaoFlatiron Health, Inc, New York, NY, USA.ORCID 0009-0003-7683-7501
Neal J MeropolFlatiron Health, Inc, New York, NY, USA.
Yihua ZhaoFlatiron Health, Inc, New York, NY, USA.

Funding

Flatiron Health, Inc
6 · The paper itself

Abstract

backgroundExpanding access to clinical trials in community settings is a potential approach to addressing disparities in accrual of historically underrepresented populations. However, little is known about the characteristics of practices that do not participate in research. We investigated differences in patient and practice characteristics of US community oncology practices with high vs low engagement in clinical research.

methodsWe included patients from a real-world, nationwide electronic health record-derived, de-identified database who received active treatment for cancer at community oncology practices between November 1, 2017, and October 31, 2022. We assessed patient and practice characteristics and their associations with high vs low research engagement using descriptive analyses and logistic regression models.

resultsOf the 178 practices, 70 (39.3%) events had high research engagement, treated 57.8% of the overall 568 540 patient cohort, and enrolled 3.25% of their patients on cancer treatment trials during the 5-year observation period (vs 0.27% enrollment among low engagement practices). Practices with low vs high research engagement treated higher proportions of the following patient groups: ages 75 years and older (24.2% vs 21.8%), non-Latinx Black (12.6% vs 10.3%) or Latinx (11.6% vs 6.1%), were within the lowest socioeconomic status quintile (21.9% vs16.5%), and were uninsured or had no documented insurance (22.2% vs 13.6%).

conclusionsPatient groups historically underrepresented in oncology clinical trials are more likely to be treated at community practices with limited or no access to trials. These results suggest that investments to expand the clinical research footprint among practices with low research engagement could help address persistent inequities in trial representation.

Indexed as

Medical OncologyNeoplasmsAdultAgedAge FactorsBiomedical ResearchBlack or African AmericanClinical Trials as TopicCommunity Health ServicesElectronic Health RecordsFemaleHealthcare DisparitiesHispanic or LatinoHumansLogistic ModelsMale

Identifiers

PMID39041606
PMCPMC11310105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.